LynxBio is a tech-enabled biotechnology company leveraging a proprietary ex vivo disease biology platform to generate multi-omic insights to accelerate the discovery and development of next-generation immuno-oncology (IO) therapies. Our platform addresses critical limitations in IO drug discovery by capturing the complex biology of dynamic cellular interactions in the tumor microenvironment and simultaneously integrating longitudinal, functional profiles with multi-omic insights to provide a holistic, systems-level understanding. Over the past 18 months, we have extensively validated our platform through six partnerships with top-10 biopharma and emerging biotech, generating >$2.5M in revenues with more to come in our expanding pipeline. LynxBio is now advancing discovery studies in collaborations & internal efforts, and we are raising our Series A to propel internal pipeline advancement and scale discovery efforts.